To gain insights into the clinical significance of RyR2 upregulation, we analyzed TCGA CRC data and demonstrated that high expression of RyR2 in CRC patients resulted in a shorter survival time (hazard ratio [HR] = 1.8, P = 0.011; Fig. 1C) as well as shorter disease‐free survival (HR = 1.6, P = 0.042; Fig. 1D). Here, RYR2 is linked to colorectal carcinoma.